Fractional Exhalation Nitric Oxide (FeNO) changes in cystic fibrosis patients induced by compound honey syrup: a pretest-posttest clinical trial

BMC Pulm Med. 2023 Dec 5;23(1):488. doi: 10.1186/s12890-023-02787-9.

Abstract

Objective: To evaluate the effect of Persian medicine Syrup 'compound honey syrup (CHS)' on fractional exhalation nitric oxide (FENO) changes in patients with cystic fibrosis (CF).

Study design: We conducted a before-after clinical trial on 70 CF patients. All patients received classical treatments for CF along with CHS (including honey, Ginger, cinnamon, saffron, cardamom and galangal), 5-10 cc (depending on the age and weight of patients) in 100 cc of warm boiled water twice a day, 30 min after meals. In this clinical trial, before and 12 weeks after the start of the CHS, FeNO test was evaluated.

Results: From 70 patients were enrolled, 44 patients completed this 12-week course of treatment. At the end of the study, changes in FeNO was significantly different before and after treatment (P-value < 0.05). At the end of the study, no dangerous side effects of CHS was reported.

Conclusions: This study revealed that CHS can be effective as a complementary and safe drug in the medication of CF patients.

Keywords: Compound honey syrup; Cystic fibrosis; FeNO; Persian Medicine.

Publication types

  • Clinical Trial

MeSH terms

  • Breath Tests
  • Cystic Fibrosis* / drug therapy
  • Exhalation
  • Honey*
  • Humans
  • Nitric Oxide

Substances

  • Nitric Oxide